– USA, NJ – Ipsen (Euronext:IPN; ADR:IPSEY) today announced that Cynthia Schwalm has been named President and CEO of Ipsen N.A., responsible for all commercial and medical affairs operations throughout the region. She will assume oversight of all areas supporting the North American Business and will report to Pierre Boulud, EVP of Specialty Care Commercial Operations.
Ms. Schwalm first joined Ipsen in February of this year and has been instrumental in building commercial capabilities and a talented leadership team in preparation for the launch of its first oncology product in the U.S. in 2015, a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs).
“Cynthia’s wealth of global experience across the pharmaceutical and biopharmaceutical industries uniquely positions her to continue to build upon the growing momentum Ipsen is experiencing in North America and internationally,” said Marc de Garidel, Chairman and CEO, Ipsen. “We remain committed to strengthening our U.S. presence and positioning the company for the level of success in the U.S. that we have achieved elsewhere.”
Ms. Schwalm is a 30-year industry veteran working in pharmaceuticals, biotechnology and medical devices. She is a member of Harvard JFK School of Public Policy Women’s Leadership Board. Ms. Schwalm earned a B.S. in nursing from the University of Delaware and a M.B.A. from Wharton School of Business at the University of Pennsylvania.
“I am excited to take on the challenge of serving as President and CEO of North America,” Schwalm stated. “We recognize the role of the U.S. in Ipsen’s goal to become a top 10 pharmaceutical company in terms of growth and profitability and are committed to improving the lives of patients.”
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trades on the over-the-counter market in the United States under the symbol IPSEY.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.